Explore

Low Adherence to Brain Health Advice Among Early Alzheimer's Patients

Low Adherence to Brain Health Advice Among Early Alzheimer's Patients

A study by the Mass General Brigham Neuroscience Institute reveals that most patients with early Alzheimer's disease are not adhering to brain health recommendations. The study, published in The Journal of Prevention of Alzheimer's Disease, found that fewer than 3% of patients followed all 15 brain health recommendations. This includes patients pursuing treatment with lecanemab, an anti-amyloid antibody medication, and those not pursuing such therapy. The findings highlight a gap in the implementation of lifestyle changes that could potentially slow cognitive decline.

Study Links Excessive Television Watching to Potential Brain Health Risks

Study Links Excessive Television Watching to Potential Brain Health Risks

A recent study has found that individuals who frequently watch television may experience reduced brain volume in areas associated with cognitive control and language. The research, funded by the National Institutes of Health, involved over 1,700 middle-aged participants who reported their television viewing habits and time spent sitting at work. The study revealed that those who watched television 'very often' had smaller brain volumes and more white matter hyperintensities, which are linked to cognitive decline and dementia. Interestingly, sedentary behavior at work did not show the same negative brain changes, suggesting that not all sedentary activities have the same impact on brain health.

Stanford Researchers Identify New Role for Tau Protein in Alzheimer's Disease

Stanford Researchers Identify New Role for Tau Protein in Alzheimer's Disease

Researchers at Stanford Medicine have discovered a new mechanism by which the tau protein, a central target in Alzheimer's drug development, damages brain cells. The study, published in Neuron, reveals that tau can infiltrate mitochondria, reversing the normal electron flow and generating reactive oxygen species, leading to cellular stress and inflammation. This discovery suggests a potential new drug target for Alzheimer's treatment. The research indicates that blocking this reversal can reduce neurodegeneration and improve learning and memory in animal models. Despite these findings, current Alzheimer's treatments remain unchanged, and no marketed supplements or interventions have been proven to affect the disease.

Creatine Shows Potential for Brain Health, But Evidence Remains Preliminary

Creatine Shows Potential for Brain Health, But Evidence Remains Preliminary

Creatine Shows Potential for Brain Health, But Evidence Remains Preliminary

Study Reveals Diverse Inflammatory Processes in Alzheimer's Disease, Impacting Treatment Approaches

Study Reveals Diverse Inflammatory Processes in Alzheimer's Disease, Impacting Treatment Approaches

A study led by researchers at the University of California, Irvine, has identified two distinct inflammatory patterns in Alzheimer's disease, each associated with different biological processes. One pattern involves damage to the brain's small blood vessels, while the other is linked to amyloid-beta buildup. Both patterns are connected to higher levels of a blood marker associated with abnormal tau, leading to brain shrinkage and memory loss. The findings suggest that Alzheimer's disease may not be driven by a single process, but rather by a combination of factors, which could explain the varied responses to treatments among patients.

Alzheimer's Drug Study Shows Potential in Reducing Brain Damage

Alzheimer's Drug Study Shows Potential in Reducing Brain Damage

A rare study of a human brain has provided insights into how an Alzheimer's drug may protect the brain by clearing amyloid plaques. Researchers from the Perelman School of Medicine at the University of Pennsylvania found that regions of the brain treated with anti-amyloid drugs showed reduced tau protein accumulation, which is associated with neuron loss and cognitive decline. This study, presented at the 2026 Alzheimer’s Association International Conference, offers evidence that removing amyloid plaques may interrupt the progression of Alzheimer's disease.

Study Reveals Brain Immune Cell Changes Linked to Alzheimer's

Study Reveals Brain Immune Cell Changes Linked to Alzheimer's

A new study has discovered that around age 50, the brain's memory center begins replacing its primary immune cells, microglia, with more inflammatory ones. This change may explain how normal aging contributes to dementia, particularly Alzheimer's disease. The research, funded by the National Institutes of Health, involved examining postmortem hippocampal tissue from neurologically healthy adults. The findings challenge the long-held belief that microglia remain in the brain for life, suggesting that the brain's immune environment changes significantly with age.

Stanford Researchers Identify New Alzheimer's Drug Target in Tau Protein

Stanford Researchers Identify New Alzheimer's Drug Target in Tau Protein

Stanford Medicine researchers have discovered a new mechanism by which the tau protein, a central target in Alzheimer's drug development, damages brain cells. The study, published in Neuron, reveals that tau infiltrates mitochondria, reversing the normal electron flow, which generates reactive oxygen species, cellular stress, and inflammation. This discovery shifts the focus from amyloid beta plaques to tau, as tau pathology correlates more closely with cognitive decline. The research suggests that blocking this reversal can reduce neurodegeneration and improve learning and memory in animal models. The study highlights the potential for tau-targeting therapies to address multiple neurodegenerative diseases, including frontotemporal dementia.

Study Reveals Long COVID Patients Have Reduced Dopamine Nerve Endings

Study Reveals Long COVID Patients Have Reduced Dopamine Nerve Endings

A recent study published in eBioMedicine has found that individuals suffering from long COVID have approximately 18% fewer dopamine nerve endings in their brains compared to healthy individuals. The research involved positron emission tomography (PET) scans of 24 adults with long COVID and 24 healthy adults, revealing significant loss of dopamine nerve endings in the striatum, a brain region crucial for movement and motivation. This loss is linked to cognitive dysfunction and could potentially lead to neurodegenerative diseases. The study highlights the persistent neurological impact of long COVID, which affects multiple organ systems and is associated with over 200 symptoms, including fatigue, memory issues, and depression.

Healthy Midlife Habits Could Delay Dementia by Up to 13 Years, Study Finds

Healthy Midlife Habits Could Delay Dementia by Up to 13 Years, Study Finds

Healthy Midlife Habits Could Delay Dementia by Up to 13 Years, Study Finds

Research Highlights Hormonal and Genetic Factors in Alzheimer's Risk for Women

Research Highlights Hormonal and Genetic Factors in Alzheimer's Risk for Women

Research Highlights Hormonal and Genetic Factors in Alzheimer's Risk for Women

Advancements in Dementia with Lewy Bodies Research Highlighted at EAN Congress

Advancements in Dementia with Lewy Bodies Research Highlighted at EAN Congress

At the European Academy of Neurology Congress 2026, experts discussed the evolving understanding of dementia with Lewy bodies (DLB), focusing on diagnosis, biological definitions, and treatment advancements. DLB, characterized by α-synuclein pathology, often coexists with Alzheimer's pathology, complicating diagnosis and treatment. The session emphasized the need for early diagnosis and the potential for biologically based disease classification. Current treatments, such as cholinesterase inhibitors, provide symptom relief, but research is ongoing for disease-modifying therapies. Phase II trials of drugs like servimecine and nilotinib show promise, though robust evidence is still needed.